A detailed history of Exane Derivatives transactions in Bio N Tech Se stock. As of the latest transaction made, Exane Derivatives holds 799 shares of BNTX stock, worth $96,455. This represents 0.08% of its overall portfolio holdings.

Number of Shares
799
Previous 704 13.49%
Holding current value
$96,455
Previous $120,000 0.83%
% of portfolio
0.08%
Previous 0.04%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 12, 2022

BUY
$123.25 - $186.24 $11,708 - $17,692
95 Added 13.49%
799 $119,000
Q1 2022

Apr 22, 2022

BUY
$126.25 - $231.85 $13,635 - $25,039
108 Added 18.12%
704 $120,000
Q4 2021

Jan 28, 2022

BUY
$216.64 - $362.52 $13,648 - $22,838
63 Added 11.82%
596 $153,000
Q3 2021

Oct 26, 2021

BUY
$205.93 - $447.23 $38,097 - $82,737
185 Added 53.16%
533 $145,000
Q2 2021

Jul 28, 2021

SELL
$113.32 - $241.49 $71,391 - $152,138
-630 Reduced 64.42%
348 $77,000
Q4 2020

Jan 27, 2021

BUY
$72.71 - $129.54 $71,110 - $126,690
978 New
978 $79,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $29.3B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.